2025-09-23 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co. (LLY) based on the data provided, presented in a clear and concise format with key metrics highlighted.

## Eli Lilly and Co. (LLY) Stock Analysis

**Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.**

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (LLY):** 228.44%
*   **Cumulative Return (VOO):** 106.97%
*   **Absolute Deviation:** 127.2
*   **Relative Deviation:** 45.6 (Indicates LLY's outperformance is in the 45.6th percentile of its historical deviation range compared to the S&P 500)

**Analysis:** LLY has significantly outperformed the S&P 500, doubling the return of the S&P 500 over the period. The relative deviation suggests this outperformance is strong within its historical context.

**Alpha, Beta Analysis (Selected Periods):**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap (B) |
| :----------- | :------ | :------ | :------ | :----- | :------ |
| 2015-2017  | 10.0%   | 56.3%   | -19.0%  | 0.0    | 76.0    |
| 2016-2018  | 39.0%   | 58.6%   | 21.0%   | -0.1   | 104.2   |
| 2017-2019  | 50.0%   | 58.6%   | 20.0%   | 0.3    | 118.3   |
| 2018-2020  | 52.0%   | 58.6%   | 33.0%   | 0.1    | 151.9   |
| 2019-2021  | 106.0%  | 60.6%   | 57.0%   | 0.2    | 248.6   |
| 2020-2022  | 98.0%   | 64.8%   | 96.0%   | 0.2    | 329.2   |
| 2021-2023  | 133.0%  | 64.8%   | 115.0%  | 0.3    | 524.6   |
| 2022-2024  | 150.0%  | 72.2%   | 124.0%  | 0.2    | 694.8   |
| 2023-2025  | 81.0%   | 76.8%   | 22.0%   | 0.2    | 676.8   |

**Analysis:**

*   **CAGR:**  Shows high growth rates, particularly in recent periods (2019-2024).
*   **MDD:** Maximum Drawdown indicates significant potential downside risk.
*   **Alpha:** Consistently positive and strong, indicating significant outperformance relative to the market risk (S&P500).
*   **Beta:** Relatively low (around 0.2-0.3 or even negative), suggesting LLY's price movements are less correlated with the overall market, or even move in the opposite direction.
*   **Cap(B):** Shows substantial growth in market capitalization over the years.

### 2. Recent Price Action

*   **Last Price:** 751.99
*   **Last Market Data:**  Price: 754.95, Previous Close: 751.99, Change: 0.39
*   **5-Day Moving Average:** 757.59
*   **20-Day Moving Average:** 741.41
*   **60-Day Moving Average:** 746.728

**Analysis:**

*   The price closed slightly higher than the previous close, indicating a modest upward movement.
*   The 5-day moving average is above the 20-day and 60-day moving averages, which suggests a short-term upward trend.
*   The current price is above both the 20-day and 60-day moving averages, implying that the stock is currently in an uptrend.

### 3. Indicators

*   **Market Risk Indicator (MRI):** 0.3367 (Low Risk)
*   **RSI:** 59.90 (Approaching overbought territory)
*   **PPO:** 0.3486
*   **Hybrid Signal:** "cash\_0% Buy 80% of cash (1 shares - Caution - MRI:0.34) Monthly invest 0.8% of total investment ($1,000.00)" (Suggests a buy signal but with caution due to the MRI)
*   **Recent (20-day) Relative Deviation Change:** 0.4 (+) (Short-term Increase)
*   **Expected Return (%):** 197.1% (Long-term Expected Excess Return vs. S&P 500)

**Analysis:**

*   The MRI indicates low market risk.
*   RSI is approaching 60 which signals the stock is gaining momentum and heading towards overbought area.
*   The hybrid signal indicates a buy signal with caution because the MRI is in the upper bound of the low risk range.
*   The positive change in relative deviation suggests recent outperformance.
*   The high expected return suggests significant potential upside over the long term.

### 4. Recent News & Significant Events

*   **Weight-Loss Drug Competition:** Articles discuss competition from Innovent and Pfizer in the GLP-1 (weight-loss drug) market.
*   **Alzheimer's Drug Performance:** An article discusses the role of Eli Lilly's Alzheimer's drug franchise in its performance.
*   **Stock as a Buy:** An article discusses whether Eli Lilly stock is a buy after a recent gain.

**Analysis:** The news highlights both opportunities and challenges for LLY.  The weight-loss drug market is becoming increasingly competitive, while the Alzheimer's drug franchise is a key area of focus.  The "is it a buy" article suggests positive sentiment but warrants further investigation.

### 4-2) Analyst Opinions

*   **Consensus:** Buy (Mean: 1.78)
*   **Target Price:** $884.31 (Average), $1190 (High), $650 (Low)

**Analysis:** Analyst sentiment is generally positive, with a "Buy" consensus. The average target price suggests potential upside from the current price. There's a significant range in target prices, indicating differing opinions on the stock's potential.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출        |
| :--------- | :--- | :---------- |
| 2025-08-07 | 6.3  | 15.56 B$    |
| 2025-05-01 | 3.07 | 12.73 B$    |
| 2024-10-30 | 1.08 | 11.44 B$    |
| 2024-08-08 | 3.29 | 11.30 B$    |
| 2025-08-07 | 3.29 | 11.30 B$    |

**Analysis:**  Recent earnings data (2024-2025) shows an upward trend in both EPS and revenue, indicating strong financial performance. The most recent EPS figure (6.3) is particularly strong.

### 6. Financial Information: Revenue, Profitability, and Capital

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-06-30 | \$15.56B | 84.27%        |
| 2025-03-31 | \$12.73B | 82.53%        |
| 2024-12-31 | \$13.53B | 82.24%        |
| 2024-09-30 | \$11.44B | 81.02%        |
| 2024-06-30 | \$11.30B | 80.80%        |

| Quarter    | Equity    | ROE       |
| :--------- | :-------- | :-------- |
| 2025-06-30 | \$18.27B | 30.98%    |
| 2025-03-31 | \$15.76B | 17.50%    |
| 2024-12-31 | \$14.19B | 31.07%    |
| 2024-09-30 | \$14.24B | 6.81%     |
| 2024-06-30 | \$13.56B | 21.88%    |

**Analysis:**

*   **Revenue:**  Increasing revenue trend over the past few quarters, indicating strong sales growth.
*   **Profit Margin:**  Very high and stable profit margins, showcasing excellent operational efficiency.
*   **Equity:**  Growing equity base, reflecting the company's increasing net worth.
*   **ROE:**  High Return on Equity, indicating efficient use of shareholder investments to generate profits.

### 7. 종합 Summary and Conclusion

Eli Lilly (LLY) exhibits a strong profile based on the provided data:

*   **Outstanding Performance:**  Significantly outperforms the S&P 500 with a high cumulative return and strong alpha.
*   **Positive Momentum:**  Recent price action suggests an uptrend, supported by moving average analysis.
*   **Strong Financials:**  Increasing revenue, high profit margins, growing equity, and high ROE demonstrate financial health.
*   **Analyst Confidence:**  Analysts have a "Buy" consensus with potential upside based on average target prices.
*   **Market Risk:** The MRI indicates that the market risk is low.
*   **High Expected Return:**  The high expected return indicates a positive outlook on returns.
*   **Competitive Landscape:** The company faces increased competition in the weight-loss drug market, which is a key area to monitor.

**Overall:** LLY appears to be a promising investment, but investors should carefully consider the competitive landscape and conduct further due diligence before making any investment decisions. The hybrid signal suggests a buy, but with caution.
